Immunity suppression by bleomycin-methotrexate combined treatment in patients with epidermoid carcinoma of the oral cavity.
D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000276:immunology*; D010478:Chemotherapy, Cancer, Regional Perfusion; D004359:Drug Therapy, Combination; D006801:Humans; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007165:Immunosuppression Therapy; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000276:immunology*; D012075:Remission, Spontaneous
D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D001761:Bleomycin; D008727:Methotrexate